Sugammadex in Crisis: Can It Save a CICV Scenario?

In this episode of NYSORA Podcast: Updates in Anesthesiology, Dr. Hadzic breaks down a 2025 systematic review by Dr. Nancy Abou Nafeh and colleagues, exploring whether sugammadex can truly rescue patients in 'cannot intubate, cannot ventilate' (CICV) emergencies. With a 75% success rate in reported cases but crucial limitations in timing, dosing, and airway obstruction, we explore the real-world utility of this rapid-reversal agent—and why it's not a magic bullet. Tune in for key clinical takeaways that may change how you prepare for your next high-risk airway.Where else to find us: Web- ⁠⁠http://www.nysora.com⁠⁠ Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ Facebook- ⁠⁠facebook.com/nysora⁠⁠ Twitter- ⁠⁠x.com/nysora⁠⁠ TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ --------------------------------------------------------- ⁠⁠#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

There are no comments yet.

Please log in to write the first comment.